API | lobeglitazone

lobeglitazone Report issue

Small molecule Experimental

AACT DrugBank Drug Central MeSH PubChem repoDB

Active Ingredient History

NOW

Lobeglitazone is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action:
- Peroxisome proliferator-activated receptor alpha (Homo sapiens) ^UniProt
- Peroxisome proliferator-activated receptor gamma (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

ckd501 | ckd 501 | ckd-501 | duvie | lobeglitazone | lobeglitazone sulfate | lobelitazone

Organizations (11)

Research & Development (11)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (1)

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (6)

Blood Glucose (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 40
# of Trial Organizations: 11

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue